By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German chemical proteomics firm Cellzome said today that it has hit a second milestone in its ongoing epigentics collaboration with GlaxoSmithKline.

The firm did not disclose the amount of the payment, but said that it comes only two months after the firm achieved a first milestone in the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.